Tandem Diabetes Care, Inc. TNDM 深 滬
等待開盤 09-18 09:30:00 美东时间
17.23
-0.300
-1.71%
華盛通- 最 高17.72
- 今 開17.72
- 成交量 221.82万股
- 最 低 16.93
- 昨 收 17.53
- 總市值 11.99亿
- 52周最高 29.65
- 市盈率 靜 --
- 換手率 3.19%
- 52周最低 11.46
- 委 比 -88.39%
- 總股本 6957.87万
- 歷史最高 302.50
- 量 比 0.94
- 振 幅 4.51%
- 歷史最低 2.14
- 每 手 1
- 風險率 3.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多William Blair Initiates Coverage On Tandem Diabetes Care with Outperform Rating
William Blair analyst Steven Lichtman initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform rating.
08-22 04:14
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the insulin pump market. Both companies have the potential to benefit from market expa...
08-22 01:31
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. Shares of Airsculpt Technologies Inc (NASDAQ:AIRS) fell sharply in pre-market trading following second-quarter results. AirSculpt Technologies posted second-quarter adjusted earnings of 1 cent per share, ...
08-10 20:02
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
RBC Capital Maintains Outperform on Tandem Diabetes Care, Lowers Price Target to $26
RBC Capital analyst Kendall Au maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and lowers the price target from $30 to $26.
08-08 04:19
财报速睇 | Tandem Diabetes Care, Inc. 2026财年Q2营收2.55亿美元，同比增长5.8%；归母净利润亏损0.21亿美元，同比亏损缩窄59.6%
华盛资讯8月7日讯，Tandem Diabetes Care, Inc.公布2026财年Q2业绩，公司Q2营收2.55亿美元，同比增长5.8%，归母净利润亏损0.21亿美元，同比亏损缩窄59.6%。
08-07 11:02
财报速睇 | Tandem Diabetes Care, Inc. 2026财年Q2营收2.55亿美元，同比增长5.8%；归母净利润亏损0.21亿美元，同比亏损缩窄59.6%
华盛资讯8月7日讯，Tandem Diabetes Care, Inc.公布2026财年Q2业绩，公司Q2营收2.55亿美元，同比增长5.8%，归母净利润亏损0.21亿美元，同比亏损缩窄59.6%。
08-07 07:45
Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.074B Est
Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion to $1.065 billion-$1.085 billion vs $1.074 billion estimate.
08-07 04:23
美股大行评级 | 潜在涨幅284.62%！Annexon获Needham上调目标价至25美元；多家大行上调美国银行目标价
今日重点评级关注：Needham：维持Annexon"买入"评级，目标价从11美元升至25美元；Benchmark：维持Prenetics Global"买入"评级，目标价从30美元升至40美元
07-16 18:55
Mizuho Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20
Mizuho analyst Anthony Petrone maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $24 to $20.
07-16 02:35
